PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21086135-7	2010	In addition, in cells induced to differentiate by ATRA or VD3, Nitroblue-tetrazolium (NBT) reduction and esterase activity, were blocked either by LY294002, a PI3K inhibitor, or by BIM, a PKC inhibitor, without affecting cell surface markers such as CD11b or CD14.	Nitroblue Tetrazolium	86-89	integrin subunit alpha M	Homo sapiens	250-255	
12677525-3	2003	The ability of HL-60 cells to reduce nitroblue tetrazolium (NBT) was significantly increased after APC treatment for 72 h. In these differentiating HL-60 cells, cell surface differentiation markers CD11b (for myeloid cells) and CD14 (for monocytic cells) were detected in 90.3 % and 70.1 % of the cells, respectively.	Nitroblue Tetrazolium	60-63	integrin subunit alpha M	Homo sapiens	198-203	
18300502-3	2007	RESULTS: The morphological changes showed cell differentiation characteristics; NBT reductant was significantly increased, and the number of NBT positive cells were related to dose of SPGL (in dose-dependent manner); Expression of CD11b and CD14 increased obviously.	Nitroblue Tetrazolium	141-144	integrin subunit alpha M	Homo sapiens	231-236	
15634573-5	2004	When ATRA + SQ22536 group compared with ATRA group, the positivity of CD11b decreased from (95.9 +/- 2.5)% to (60.3 +/- 7.1)%, while the A(540) in NBT reduction assay decreased from 0.585 +/- 0.092 to 0.170 +/- 0.028 (P < 0.05).	Nitroblue Tetrazolium	147-150	integrin subunit alpha M	Homo sapiens	70-75	
15634573-7	2004	When ATRA + forskolin group compared with ATRA group, the positivity of CD11b increased from (34.3 +/- 5.3)% to (94.6 +/- 2.4)%, while the A(540) in NBT reduction assay increased from 0.110 +/- 0.028 to 0.395 +/- 0.049 (P < 0.05).	Nitroblue Tetrazolium	149-152	integrin subunit alpha M	Homo sapiens	72-77